Case ID,Bilateral Case,Regimen,Pathology Markers,Simulation ID,Start Volume,Final Volume,Response %,pCR Call (Volume < 0.01 or Response >99.9),pCR Call With Dose Reductions,Residual Tumor Bed(mm),Age,Race,Type,Grade,ER Score,PR Score,HER2 IHC,HER2 FISH,Regimen Type,Regimen Schedule/Description,pCR,ypT0,Alive,Progressed,EFS Days / Censor,Survival Days / Censor,Cellularity,Positive LN,Diameter largest LN metastasis (mm) ,T Stage,N Stage,M Stage,Stage Group
UCHI_1001_1,Yes,TCH,HR+/HER2-,sim-1a2QbTvDXg,0.363375,0.066072,81.8,Residual,Residual,6.8 x 5.9 x 4.8,61,African American,Invasive Ductal Carcinoma,1,90,20,1+,,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,No,No,3173.00,3173.00,1,0 of 1,0,T1c,N0,M0,Ia
UCHI_1001_2,Yes,TCH,HR-/HER2+,sim-3hSLhDhrQ4,12.124,0.006903,99.9,pCR,pCR,0 x 0 x 0,61,African American,Invasive Ductal Carcinoma,3,0,0,3+,,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",Yes,Yes,No,No,3173.00,3173.00,0,0 of 2,0,T1c,N0,M0,Ia
UCHI_1002,,ddAC-wT,TNBC,sim-bsKn6FSHxg,22.75775,0.337154,98.5,Residual,Residual,48.8 x 32.9 x 22.2,59,Asian,Invasive Ductal Carcinoma,3,5,0,2+,1.2,Uncertain,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
8 cycles of paclitaxel every 1 weeks",No,No,No,Yes,298.00,468.00,20,4 of 11,20,T3,N2,M0,IIIa
UCHI_1003,,wT-ddAC,TNBC,sim-Be2T42QScY,12.735875,0.021658,99.8,Residual,Residual,45.8 x 34.8 x 26.4,74,Native American,Invasive Ductal Carcinoma,3,0,0,-,0.7,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1215.00,1215.00,50,0 of 6,0,T2,N0,M0,IIa
UCHI_1004,,wT-ddAC,HR+/HER2-,sim-7aaXNLdTCJ,3.8235,0.019388,99.5,Residual,Residual,41.9 x 20.1 x 11.3,49,African American,Invasive Ductal Carcinoma,2,30,10,1+,2.36,Modified (Dose Reduction),"12 cycles of paclitaxel,trastuzumab every 1 weeks
3 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,Yes,1044.00,1618.00,,12 of 22,11,T1c,N1,M0,IIa
UCHI_1005,,wT-ddAC,TNBC,sim-5zapPNbVdA,4.948875,0.472243,90.5,Residual,Residual,40.4 x 15 x 9.7,53,African American,Invasive Ductal Carcinoma,3,0,0,-,0.91,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3675.00,3675.00,,0 of 4,0,T2,N0,M0,IIa
UCHI_1006,,TCH,HR-/HER2+,sim-5sxtPgKyD8,5.87825,0.001299,100,pCR,pCR,0 x 0 x 0,73,Caucasian,Invasive Ductal Carcinoma,3,5,0,2+,5.4,Uncertain,"2 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
10 cycles of trastuzumab every 1 weeks",Yes,Yes,Yes,No,3160.00,3160.00,0,0 of 3,0,T3,N3b,M0,IIIc
UCHI_1007,,wT-ddAC,HR+/HER2-,sim-DMHTcMJYha,8.579,0.003456,100,pCR,pCR,0 x 0 x 0,73,African American,Invasive Ductal Carcinoma,3,20,0,-,0.98,Modified (Dose reduced T),"8 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,No,No,3182.00,3182.00,0,0 of 14,0,T2,N1,M0,IIb
UCHI_1009,,wT-ddAC,TNBC,sim-DkeCFwSLRx,4.279625,1.057868,75.3,Residual,Residual,16.2 x 15.1 x 14.7,64,African American,Invasive Ductal Carcinoma,3,0,0,-,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3964.00,3964.00,<5,1 of 32,4,T1c,N1,M0,IIa
UCHI_1010,,wT-ddAC,TNBC,sim-seQGcQ7eNb,7.57175,0.031917,99.6,Residual,Residual,20.4 x 18.9 x 17.4,77,African American,Invasive Ductal Carcinoma,3,0,1,-,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2432.00,2432.00,<1,0 of 1,0,T2,N0,M0,IIa
UCHI_1011,,wT-ddAC,TNBC,sim-6v9PMeMfXE,4.43425,0.232684,94.8,Residual,Residual,71.8 x 70.7 x 28.9,58,African American,Invasive Ductal Carcinoma,3,1,1,-,1.2,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 3 weeks",Yes,Yes,Yes,No,1294.00,1294.00,0,0 of 4,0,T1b,N1,M0,IIa
UCHI_1012,,ddAC-wT,TNBC,sim-YZvBfDtVyt,23.522375,0.000566,100,pCR,pCR,0 x 0 x 0,45,African American,Invasive Ductal Carcinoma,3,10,0,-,1.1,Modified (Dose reduced T),"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
12 cycles of paclitaxel every 1 weeks",Yes,Yes,Yes,No,2016.00,2016.00,0,0 of 4,0,T2,N2,M0,IIIa
UCHI_1013,,TCH,TNBC,sim-K6t3AMtgK7,4.224625,0.032896,99.2,Residual,Residual,17.5 x 8.8 x 8.4,71,Other,Invasive Lobular Carcinoma,3,0,0,-,1.53,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks",No,No,No,Yes,263.00,401.00,40,2 of 12,15,T2,N1,M0,IIb
UCHI_1014,,wT-ddAC,TNBC,sim-fHbprH98PF,9.10925,0.000162,100,pCR,pCR,0 x 0 x 0,70,African American,Invasive Ductal Carcinoma,3,0,0,-,1,Modified (Dose reduced T),"7 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,2712.00,2712.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1015,,TC,TNBC,sim-gSxH16666F,0.53175,1.10E-05,100,pCR,pCR,0 x 0 x 0,66,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,1.07,Standard,"4 cycles of cyclophosphamide,docetaxel every 3 weeks",Yes,Yes,Yes,No,1146.00,1146.00,0,0 of 3,0,T1c,N0,M0,Ia
UCHI_1019,,ddAC-TCarbo,TNBC,sim-UwmaA3TGam,15.900875,0.249021,98.4,Residual,Residual,83.1 x 42.3 x 20.8,47,African American,Invasive Ductal Carcinoma,3,0,2,2+,1.55,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3598.00,3598.00,90,0 of 19,0,T2,N1,M0,IIb
UCHI_1020,,wT-ddAC,HR+/HER2-,sim-VxQrpCLB2g,4.1655,2.94271,29.4,Residual,Residual,27.3 x 19.7 x 17.7,54,African American,Invasive Ductal Carcinoma,3,90,90,-,1.05,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2961.00,2961.00,5,1 of 23,3,T1,N1,M0,IIa
UCHI_1022,,THP,HR+/HER2+,sim-npesvxC2Gc,47.491625,0.750128,98.4,Residual,Residual,63.4 x 46.7 x 26.3,68,African American,Invasive Ductal Carcinoma,2,95,0,+,13.9,Modified(Only 4 T cycles),"4 cycles of docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycles of trastuzumab_TP every 3 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 3 weeks
2 cycles of trastuzumab_TP every 3 weeks",No,No,Yes,No,1652.00,1652.00,5,0 of 2,0,T2,N0,M0,IIa
UCHI_1023,,wTHP-ddAC,HR+/HER2+,sim-Qma1grdNSZ,111.067375,0.04591,100,pCR,pCR,0 x 0 x 0,35,African American,Invasive Ductal Carcinoma,3,90,10,3+,3.7,Standard,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of trastuzumab_TP",Yes,Yes,Yes,No,2486.00,2486.00,0,0 of 2,0,T3,N1,M0,IIIa
UCHI_1024,,wTH-ddAC,HR-/HER2+,sim-n3wJKW2BSe,21.428,8.681696,59.5,Residual,Residual,31.9 x 31.5 x 26.8,59,African American,Invasive Ductal Carcinoma,3,0,0,2+,2.08,Uncertain,"6 cycles of trastuzumab every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3622.00,3622.00,,0 of 2,0,T2,N0,M0,IIa
UCHI_1025,,TCH,HR+/HER2+,sim-QRKyp1fLAP,20.79425,0.786626,96.2,Residual,Residual,47.2 x 31.1 x 29.9,63,African American,Invasive Ductal Carcinoma,3,30,20,+,9.7,Modified(Schedule),"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,No,No,2357.00,2357.00,60,5 of 23,2.1,T2,N0,M0,IIa
UCHI_1026,,wT-ddAC,TNBC,sim-hZnYAvgRv4,38.70525,17.209963,55.5,Residual,Residual,56.7 x 44.4 x 29.9,61,African American,Invasive Ductal Carcinoma,3,0,0,-,1,Modified (Dose reduced T & AC),"12 cycles of paclitaxel every 1 weeks
2 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,No,2414.00,2414.00,<1,0 of 2,0,T3,N0,M0,IIb
UCHI_1027,,wT-ddAC,TNBC,sim-E3MQm4y5Xz,17.118875,3.174377,81.5,Residual,Residual,37.5 x 36.3 x 31.5,62,African American,Invasive Ductal Carcinoma,3,10,0,-,1.4,Modified (Dose reduced T),"9 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2514.00,2514.00,<1,0 of 2,0,T2,N1,M0,IIb
UCHI_1028,,TCH-ddAC,HR+/HER2+,sim-ndWzn9kmFC,28.31225,0.058263,99.8,Residual,pCR,87.6 x 36.7 x 30.8,63,African American,Invasive Ductal Carcinoma,2,90,50,+,2.44,Modified,"2 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3578.00,3578.00,,0 of 12,0,T1,N0,M0,Ia
UCHI_1030,,wT-ddAC,TNBC,sim-GyCHzvcKxK,6.79575,0.031711,99.5,Residual,Residual,11.4 x 10.3 x 6.6,48,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,Modified (Dose reduced T),"11 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,Yes,763.00,1088.00,40,0 of 2,0,T2,N1,M0,IIb
UCHI_1031,,wT-ddAC,TNBC,sim-DCUH5vQeeP,282.350875,35.926656,87.3,Residual,Residual,100.8 x 95.5 x 43.9,33,African American,Invasive Ductal Carcinoma,3,0,0,1+,1.2,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2104.00,2104.00,10,2 of 5,2.5,T3,N1,M0,IIIa
UCHI_1032,,wT-ddAC,TNBC,sim-J3ssRQU7Eb,35.52975,3.156642,91.1,Residual,Residual,96.7 x 69.6 x 42.3,62,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,Modified (Dose reduced T),"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,811.00,811.00,20,1 of 17,3,T2,N1,M0,IIb
UCHI_1035,,wT-ddAC,HR+/HER2-,sim-ZpJ2RvwHhP,3.507375,0.022234,99.4,Residual,Residual,14.1 x 10.6 x 9.1,28,African American,Invasive Ductal Carcinoma,2,90,77,-,,Modified (Dose Reduction),"12 cycles of paclitaxel every 1 weeks
3 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3128.00,3128.00,5,0 of 5,0,T2,N0,M0,IIa
UCHI_1036,,TCHP,HR-/HER2+,sim-RAhX6WScbr,6.3825,0.002763,100,pCR,pCR,0 x 0 x 0,61,Other,Invasive Ductal Carcinoma,3,0,0,+,3.5,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of pertuzumab_TP,trastuzumab_TP",Yes,Yes,Yes,No,1429.00,1429.00,0,0 of 1,0,T2,N1,M0,IIb
UCHI_1040,,ddAC-T,TNBC,sim-1f9V3TKzPR,5.631875,0.000705,100,pCR,pCR,0 x 0 x 0,49,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
4 cycles of paclitaxel every 2 weeks",Yes,Yes,Yes,No,1904.00,1904.00,0,0 of 2,0,T2,N0,M0,IIa
UCHI_1041,,TCHP,HR-/HER2+,sim-aZxsMV11HR,4.039375,0.003512,99.9,pCR,pCR,0 x 0 x 0,77,African American,Invasive Ductal Carcinoma,3,0,0,3+,8.3,Uncertain,"2 cycles of carboplatin_TP,paclitaxel every 3 weeks
3 cycles of carboplatin_TP,paclitaxel,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",Yes,Yes,No,No,442.00,442.00,0,0 of 4,0,T2,N0,M0,IIa
UCHI_1042,,TCH,HR+/HER2+,sim-wA8RxU3pQ4,12.361375,0.989025,92,Residual,Residual,39.8 x 19.9 x 16,70,African American,Invasive Ductal Carcinoma,3,90,10,+,3.8,Standard,"4 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
2 cycles of carboplatin,trastuzumab every 3 weeks",Yes,Yes,Yes,No,3459.00,3459.00,0,0 of 23,0,T2,N1,M0,IIb
UCHI_1043,,wT-ddAC,TNBC,sim-ET8m5NAspa,28.302625,0.00108,100,pCR,pCR,0 x 0 x 0,23,African American,Invasive Ductal Carcinoma,3,0,1,1+,1.31,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3742.00,3742.00,0,0 of 20,0,T3,N1,M0,IIIa
UCHI_1044,,wT-ddAC,HR+/HER2-,sim-3Ccr1UdLRp,9.944875,0.030972,99.7,Residual,Residual,60.3 x 29.7 x 27.1,39,African American,Invasive Lobular Carcinoma,2,90,60,-,,Modified,FAILED: goserelin,No,No,Yes,No,2344.00,2344.00,10,0 of 23,0,T1c,N2,M0,IIIa
UCHI_1046,,wT-ddAC,HR+/HER2-,sim-JYZvcFmf5C,109.559625,15.527536,85.8,Residual,Residual,62.5 x 56.8 x 42.3,57,Caucasian,Invasive Ductal Carcinoma,3,20,0,-,1.9,Modified (See Schedule),"8 cycles of paclitaxel every 1 weeks
5 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1002.00,1002.00,15,0 of 2,0,T3,N1,M0,IIIa
UCHI_1047,,wT-ddAC,TNBC,sim-D3ANFhMWzW,13.002,5.60E-05,100,pCR,pCR,0 x 0 x 0,60,African American,Invasive Ductal Carcinoma,3,1,0,-,1.24,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,Yes,Yes,No,3218.00,3218.00,0,2 of 13,2.5,T2,N1,M0,IIb
UCHI_1049,,TC,HR+/HER2-,sim-95ZXRybeA9,19.947875,11.885395,40.4,Residual,Residual,59.9 x 39.5 x 34.8,72,African American,Invasive Lobular Carcinoma,2,40,40,-,1.13,Standard,"4 cycles of cyclophosphamide,docetaxel every 3 weeks",No,No,No,Yes,1486.00,1683.00,10,12 of 18,7,T3,N3,M0,IIIc
UCHI_1052,,TCH,HR+/HER2+,sim-4bfbyC4Qw3,1.14875,0.038945,96.6,Residual,Residual,18 x 10.6 x 5.8,55,Caucasian,Invasive Ductal Carcinoma,2,80,80,+,11.4,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,Yes,No,3548.00,3548.00,,0 of 4,0,T2,N0,M0,IIa
UCHI_1055,,wT-ddAC,TNBC,sim-JCAyNDPYEw,3.27475,3.30E-05,100,pCR,pCR,0 x 0 x 0,47,African American,Invasive Ductal Carcinoma,3,0,1,-,1.3,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,1394.00,1394.00,0,0 of 3,0,T1c,N1,M0,IIa
UCHI_1057,,TCH,HR-/HER2+,sim-aLJABTNWKc,4.17875,0.002015,100,pCR,pCR,0 x 0 x 0,67,Caucasian,Invasive Ductal Carcinoma,3,0,0,3+,,Uncertain,EMPTY,Yes,Yes,Yes,No,2628.00,2628.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1058,,TCH,HR+/HER2+,sim-x8h3gcz7xd,5.401125,0.111367,97.9,Residual,Residual,70.7 x 20.1 x 19.1,53,African American,Invasive Ductal Carcinoma,2,90,15,3+,,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",Yes,Yes,Yes,No,3269.00,3269.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1059,,wT-ddAC,TNBC,sim-MVxPKm76bG,12.65675,0.806958,93.6,Residual,Residual,96.9 x 55 x 40.2,54,,Invasive Ductal Carcinoma,3,0,0,2+,1.07,Standard,FAILED: eribulin,No,No,No,Yes,313.00,1449.00,70,0 of 3,0,T2,N0,M0,IIa
UCHI_1060,,wT-ddAC,TNBC,sim-tDbaSvkJQd,17.41875,3.666271,79,Residual,Residual,57.7 x 42.3 x 23.7,48,African American,Invasive Ductal Carcinoma,3,0,0,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2515.00,2515.00,<1,0 of 3,0,T2,N1,M0,IIb
UCHI_1062,,TCH,HR+/HER2+,sim-GrB2KaM6LZ,8.212125,0.158489,98.1,Residual,Residual,47.9 x 42.6 x 27.6,38,African American,Invasive Ductal Carcinoma,2,60,80,3+,6.7,Modified(Dose Modified),"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,Yes,No,3628.00,3628.00,,0 of 6,0,T3,N1,M0,IIIa
UCHI_1064,,TCH,HR-/HER2+,sim-vJrsXJDH7V,3.33925,0.009874,99.7,pCR,pCR,0 x 0 x 0,45,African American,Adenocarcinoma,2,0,0,2+,11.3,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",Yes,Yes,Yes,No,3635.00,3635.00,0,0 of 4,0,T2,N1,M0,IIb
UCHI_1066,,ddAC-wT,TNBC,sim-yPB745UBpF,17.60625,1.463447,91.7,Residual,Residual,64 x 23.5 x 22.1,52,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,"Modified (10 T cycles - dose reduced, 1 week extra gap in last AC cycle)","4 cycles of cyclophosphamide,doxorubicin every 2 weeks
10 cycles of paclitaxel every 1 weeks",No,No,Yes,No,1327.00,1327.00,15,0 of 3,0,T2,N0,M0,IIa
UCHI_1067,,wTHP-ddAC,HR-/HER2+,sim-Ct1XEJa51z,8.5075,6.20E-05,100,pCR,pCR,0 x 0 x 0,43,African American,Invasive Ductal Carcinoma,3,0,0,2+,2.2,Modified (See Schedule),"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,716.00,716.00,0,0 of 2,0,T2,N0,M0,IIb
UCHI_1068,,TCHP,HR-/HER2+,sim-e1B4Q13S8G,3.837125,0.000107,100,pCR,pCR,0 x 0 x 0,56,African American,Invasive Ductal Carcinoma,3,10,0,+,13.3,Standard,"4 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
2 cycles of docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",Yes,Yes,Yes,No,1843.00,1843.00,0,0 of 5,0,T2,N0,M0,IIa
UCHI_1069,,TC,TNBC,sim-rfgsXEzFnT,19.0455,0.041681,99.8,Residual,Residual,60.2 x 41 x 27.7,56,African American,Invasive Ductal Carcinoma,3,0,0,-,1.38,Uncertain,"2 cycles of cyclophosphamide,docetaxel every 3 weeks",No,No,Yes,No,756.00,756.00,10,0 of 4,0,T3,N1,M0,IIIa
UCHI_1070,,wT-ddAC,HR+/HER2-,sim-UVENNZNPP3,4.29475,0.016003,99.6,Residual,Residual,17.3 x 16.1 x 10.3,41,Caucasian,Invasive Ductal Carcinoma,2,90,75,1+,1.4,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2401.00,2401.00,30,1 of 29,7.5,T3,N0,M0,IIb
UCHI_1071,,wT-ddAC,TNBC,sim-QB4mtTWAKb,22.90975,4.170996,81.8,Residual,Residual,86.6 x 54.4 x 52.5,59,,Invasive Ductal Carcinoma,3,0,0,1+,,Modified (Dose reduced T),"10 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,315.00,315.00,5,11 of 13,40,T2,N1,M0,IIb
UCHI_1073,,ddAC-wT,HR+/HER2-,sim-YtXd4W11kD,0.7655,0.005959,99.2,pCR,pCR,0 x 0 x 0,43,Caucasian,Invasive Ductal Carcinoma,3,95,5,-,,Standard,FAILED: 'float' object has no attribute 'split',No,Yes,Yes,No,1981.00,1981.00,0,1 of 5,2.1,T2,N1,M0,IIb
UCHI_1074,,ddAC-TCarbo,HR+/HER2-,sim-NGGBMbKzRk,2.637,6.80E-05,100,pCR,pCR,0 x 0 x 0,45,Caucasian,Invasive Ductal Carcinoma,3,15,0,-,1.1,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
4 cycles of carboplatin,docetaxel every 3 weeks",Yes,Yes,Yes,No,2209.00,2209.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1075,,wT-ddAC,HR+/HER2-,sim-23azxPcy5X,4.564375,0.498308,89.1,Residual,Residual,20 x 19.7 x 17.2,53,African American,Invasive Ductal Carcinoma,2,90,0,-,0.3,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1173.00,1173.00,1,0 of 1,0,T2,N1,M0,IIb
UCHI_1076,,THP,HR-/HER2+,sim-5E7UvbaYn7,10.7545,0.005793,99.9,pCR,pCR,0 x 0 x 0,64,African American,Invasive Ductal Carcinoma,3,0,0,+,5.8,Standard,"2 cycles of docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
4 cycles of docetaxel_TP,trastuzumab_TP every 3 weeks
2 cycles of trastuzumab_TP every 3 weeks",Yes,Yes,Yes,No,2341.00,2341.00,0,0 of 2,0,T1c,N0,M0,Ia
UCHI_1077,,TCHP,HR-/HER2+,sim-EK7dhSUH6S,8.002125,0.001595,100,pCR,pCR,0 x 0 x 0,57,Caucasian,Invasive Ductal Carcinoma,2,0,0,3+,7.8,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks",Yes,Yes,Yes,No,1320.00,1320.00,0,0 of 1,0,T2,N0,M0,IIa
UCHI_1078,,wTH-ddAC,TNBC,sim-6QMYLABPZh,25.147125,6.539182,74,Residual,Residual,55.1 x 48.7 x 48.6,58,African American,Invasive Ductal Carcinoma,3,0,0,1+,1.13,Modified (See Schedule),"12 cycles of paclitaxel,trastuzumab every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,No,3632.00,3632.00,10,0 of 2,0,T3,N0,M0,IIb
UCHI_1079,,TC,TNBC,sim-JNa7AAvbU4,35.719875,0.059144,99.8,Residual,Residual,69.8 x 47.3 x 36.6,52,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,1.08,Standard,"4 cycles of cyclophosphamide,docetaxel every 3 weeks",No,No,Yes,No,3574.00,3574.00,30,1 of 19,14,T2,N3b,M0,IIIc
UCHI_1080,,ddAC-wT,HR+/HER2-,sim-wESVAKszAH,0.481875,0.010421,97.8,Residual,pCR,36.3 x 9.6 x 3.9,56,Caucasian,Invasive Ductal Carcinoma,3,90,10,2+,1.1,Modified(Only 3 T cycles),"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
3 cycles of paclitaxel every 1 weeks",No,No,Yes,No,499.00,499.00,2,1 of 4,2,T1b,N1,M0,
UCHI_1081,,wT-ddAC,TNBC,sim-SVrEgwp16J,8.96075,0.268848,97,Residual,Residual,25.2 x 20.9 x 17.9,58,Caucasian,Invasive Ductal Carcinoma,3,0,0,1+,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,2564.00,2564.00,0,0 of 4,0,T2,N0,M0,IIa
UCHI_1082,,AC,TNBC,sim-NPX146PHKS,7.719,0.002288,100,pCR,pCR,0 x 0 x 0,50,African American,Invasive Ductal Carcinoma,3,10,0,-,1.06,Standard,"4 cycles of cyclophosphamide,doxorubicin every 3 weeks",Yes,Yes,Yes,No,3585.00,3585.00,0,0 of 5,,T2,N0,M0,IIa
UCHI_1083,,wTHP-ddAC,TNBC,sim-Ze5CSX5167,12.4215,0.049945,99.6,Residual,Residual,44.9 x 44.6 x 43.1,75,African American,Invasive Ductal Carcinoma,3,0,0,1+,1.2,Modified (Dose reduced T),"4 cycles of paclitaxel every 0 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 4 weeks
1 cycle of pertuzumab_TP,trastuzumab_TP",No,No,Yes,No,1283.00,1283.00,1,1 of 9,3,T2,N1,M0,IIb
UCHI_1084,,wT-ddAC,HR+/HER2-,sim-kTBKpdmLY1,4.612375,0.810346,82.4,Residual,Residual,104.6 x 87.4 x 22.4,42,African American,Invasive Ductal Carcinoma,3,25,0,-,1.5,Modified (Dose reduced T),"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2283.00,2283.00,10,0 of 1,0,T1c,N0,M0,Ia
UCHI_1086,,wT-ddAC,TNBC,sim-ZYwcrQRVt8,1.39325,0.00264,99.8,pCR,pCR,0 x 0 x 0,61,Other,Invasive Ductal Carcinoma,3,0,0,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1423.00,1423.00,,0 of 3,0,T1,N0,M0,Ia
UCHI_1087,,wT-ddAC,TNBC,sim-Hm4tPMpQfk,4.017375,2.50E-05,100,pCR,pCR,0 x 0 x 0,42,Caucasian,Invasive Ductal Carcinoma,3,10,0,-,1.3,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,1440.00,1440.00,0,0 of 3,0,T2,N1,M0,IIb
UCHI_1088,,wT-ddAC,HR+/HER2-,sim-cwGEbXDAKy,2.379875,0.61424,74.2,Residual,Residual,16.5 x 14 x 9.2,55,Caucasian,Invasive Ductal Carcinoma,3,94,25,-,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1422.00,1422.00,10,0 of 4,0,T4,N0,M0,IIIb
UCHI_1089,,TCH,HR+/HER2+,sim-AtkRH7Re1Q,4.011625,0.69415,82.7,Residual,Residual,72.6 x 18.6 x 15.4,34,African American,Invasive Ductal Carcinoma,2,80,5,+,9.4,Standard,"6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,Yes,No,3450.00,3450.00,50,0 of 3,0,T2,N0,M0,IIa
UCHI_1090,,wT-ddAC,TNBC,sim-19R8skYnJz,227.411125,0.031801,100,pCR,pCR,0 x 0 x 0,37,African American,Invasive Ductal Carcinoma,3,0,0,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,860.00,860.00,0,0 of 24,0,T3,N2b,M0,IIIa
UCHI_1091,,TCHP,HR+/HER2+,sim-fmQB8YGHGN,5.19425,0.010637,99.8,Residual,pCR,22 x 16.2 x 10.8,56,African American,Invasive Ductal Carcinoma,3,90,60,3+,,Modified,"5 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1170.00,1170.00,1,0 of 3,0,T2,N0,M0,IIa
UCHI_1092,,wT-ddAC,TNBC,sim-58KXQ8Jz24,25.19075,0.335275,98.7,Residual,Residual,53.4 x 40.2 x 29.8,57,,Invasive Ductal Carcinoma,3,0,0,-,1.4,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,553.00,553.00,50,0 of 2,0,T2,N0,M0,
UCHI_1093,,TCHP,HR-/HER2+,sim-h89kWY6FWk,1.860375,3.00E-06,100,pCR,pCR,0 x 0 x 0,56,Caucasian,Invasive Ductal Carcinoma,3,0,0,+,6.4,Uncertain,"1 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycles of carboplatin_TP,docetaxel_TP,trastuzumab_TP every 3 weeks
4 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
11 cycles of trastuzumab_TP every 3 weeks",Yes,Yes,Yes,No,2395.00,2395.00,0,0 of 18,,T1c,N1,M0,IIa
UCHI_1096,,wT-ddAC,TNBC,sim-fCNSPYWEPt,8.815625,0.000188,100,pCR,pCR,0 x 0 x 0,48,,Invasive Ductal Carcinoma,3,0,1,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,677.00,677.00,0,0 of 4,0,T2,N0,M0,
UCHI_1097,,wT-ddAC,TNBC,sim-r9zJSvsUMA,3.346875,2.90E-05,100,pCR,pCR,0 x 0 x 0,44,Caucasian,Invasive Ductal Carcinoma,3,0,0,1+,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3002.00,3002.00,0,0 of 4,0,T2,N0,M0,IIa
UCHI_1098,,TCHP,HR+/HER2+,sim-bpspZVpG6B,17.469625,0.083187,99.5,Residual,Residual,76.4 x 41.4 x 32.4,28,African American,Invasive Ductal Carcinoma,3,80,50,+,6.9,Modified,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1999.00,1999.00,<5,0 of 5,0,T1b,N1,M0,IIa
UCHI_1099,,wT-ddAC,HR+/HER2-,sim-p1GDfGA4Gb,9.615875,0.048149,99.5,Residual,Residual,34.7 x 30.1 x 17.5,63,African American,Invasive Ductal Carcinoma,3,90,20,-,1.35,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,Yes,680.00,689.00,<5,6 of 18,5,T2,N1,M0,IIb
UCHI_1100_1,Yes,wT-ddAC,HR+/HER2-,sim-af2PpvUnyy,0.437,0.001396,99.7,pCR,pCR,0 x 0 x 0,55,Caucasian,Invasive Ductal Carcinoma,1,95,0,-,,Modified,"11 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1938.00,1938.00,,0 of 5,0,T1c,N0,M0,Ia
UCHI_1100_2,Yes,wT-ddAC,TNBC,sim-ZBfMAEGmHe,3.55625,0.000262,100,pCR,pCR,0 x 0 x 0,55,Caucasian,Invasive Ductal Carcinoma,2,0,0,-,,Modified,"11 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,1938.00,1938.00,0,0 of 2,0,T2,N0,M0,IIa
UCHI_1102,,TC,HR+/HER2-,sim-5DPATMbUV2,10.741875,3.562731,66.8,Residual,Residual,63.5 x 58 x 37.8,30,Asian,Invasive Ductal Carcinoma,2,90,60,1+,,Standard,"4 cycles of cyclophosphamide,docetaxel every 3 weeks",No,No,Yes,Yes,1286.00,2378.00,20,0 of 5,0,T2,N0,M0,IIa
UCHI_1103,,wT-ddAC,TNBC,sim-9wVe39xv8d,1.829625,1.10E-05,100,pCR,pCR,0 x 0 x 0,55,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3721.00,3721.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1108,,wT-ddAC,HR+/HER2-,sim-HnRAw53m7a,10.104375,0.250005,97.5,Residual,Residual,85.8 x 73.9 x 44.2,51,African American,Invasive Lobular Carcinoma,3,80,5,-,1.5,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,Yes,1385.00,1764.00,50,12 of 13,12,T1c,N1,M0,IIa
UCHI_1109,,wT,TNBC,sim-pmzUnmy9kM,2.184625,0.153447,93,Residual,Residual,23.7 x 9.9 x 6.9,76,African American,Invasive Ductal Carcinoma,3,0,0,1+,0.96,Standard,12 cycles of paclitaxel every 1 weeks,No,No,Yes,No,1052.00,1052.00,,0 of 4,0,T1c,N0,M0,Ia
UCHI_1110,,ddAC-T,TNBC,sim-n1rH5VJkN5,12.864625,0.225662,98.2,Residual,Residual,34.5 x 26.6 x 16.9,73,African American,Invasive Ductal Carcinoma,3,0,0,2+,2.01,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
4 cycles of paclitaxel every 2 weeks",No,No,No,No,583.00,699.00,80,0 of 3,0,T3,N0,M0,IIb
UCHI_1111,,TCHP,HR-/HER2+,sim-7reN1tBPTA,1.73375,0.000375,100,pCR,pCR,0 x 0 x 0,71,Caucasian,Invasive Ductal Carcinoma,3,0,0,3+,12.7,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",Yes,Yes,Yes,No,1613.00,1613.00,0,0 of 2,0,T2,N0,M0,IIa
UCHI_1113,,wT-ddAC,HR+/HER2-,sim-vQev76pF8U,22.168375,0.112689,99.5,Residual,Residual,60.1 x 29.2 x 16.5,48,Caucasian,Invasive Ductal Carcinoma,2,90,90,-,1,Uncertain,FAILED: goserelin,No,No,Yes,No,2921.00,2921.00,,0 of 3,0,T3,N0,M0,IIb
UCHI_1114,,TCH,HR-/HER2+,sim-z7gN7eQr1z,4.905125,0.001399,100,pCR,pCR,0 x 0 x 0,62,Other,Invasive Ductal Carcinoma,3,0,0,3+,5.6,Uncertain,EMPTY,Yes,Yes,Yes,No,363.00,363.00,0,0 of 6,0,T2,N0,M0,IIa
UCHI_1115,,wT-ddAC,TNBC,sim-UAUTwnxvpV,5.227,3.169653,39.4,Residual,Residual,67.9 x 53.6 x 19.8,57,African American,Invasive Ductal Carcinoma,3,0,0,-,1.2,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3783.00,3783.00,1,0 of 2,0,T2,N0,M0,IIa
UCHI_1117,,ddAC-T,TNBC,sim-KCUGQ2A2Xg,146.357875,0.19665,99.9,pCR,pCR,0 x 0 x 0,69,Caucasian,Invasive Ductal Carcinoma,3,0,0,1+,1.15,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
4 cycles of paclitaxel every 2 weeks",Yes,Yes,Yes,No,3783.00,3783.00,0,0 of 2,0,T4d,N1,M0,IIIb
UCHI_1119,,ddAC-T,HR+/HER2-,sim-UNv5EtcZK9,27.348875,0.392488,98.6,Residual,Residual,56.5 x 40.1 x 15.4,61,African American,Invasive Ductal Carcinoma,2,90,0,-,1,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
4 cycles of paclitaxel every 2 weeks",No,No,No,Yes,491.00,919.00,30,8 of 13,10,T3,N2,M0,IIIa
UCHI_1122,,TCHP,TNBC,sim-YQ5AWdgXb6,3.847875,0.023235,99.4,Residual,Residual,69 x 20.7 x 12.2,42,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,12,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,No,Yes,612.00,912.00,>90,5 of 29,12,T2,N2,M0,IIIa
UCHI_1123,,wTH - ddAC,HR-/HER2+,sim-5m8EMx1fn3,3.620125,9.00E-06,100,pCR,pCR,0 x 0 x 0,43,Other,Invasive Ductal Carcinoma,2,0,0,+,7.81,Uncertain,EMPTY,Yes,Yes,Yes,No,714.00,714.00,0,0 of 4,0,T2,N0,M0,IIa
UCHI_1124,,wT-ddAC,HR+/HER2-,sim-sQzR6LzF5y,4.281,0.017495,99.6,Residual,Residual,24.7 x 18 x 13.2,35,Other,Invasive Ductal Carcinoma,3,0,50,1+,4.8,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,Yes,370.00,405.00,<10,1 of 5,1,T2,N1,M0,Ib
UCHI_1125,,wTH-ddAC,HR+/HER2+,sim-FYfsFCwgmY,2.141375,0.01139,99.5,Residual,Residual,11 x 6.6 x 6.2,55,African American,Invasive Ductal Carcinoma,3,80,60,+,9.5,Standard,"12 cycles of paclitaxel,trastuzumab every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3361.00,3361.00,<5,0 of 4,0,T2,N0,M0,IIa
UCHI_1126,,wTH-ddAC,HR-/HER2+,sim-CgaBJw4sUa,4.314875,0.001004,100,pCR,pCR,0 x 0 x 0,56,Asian,Invasive Ductal Carcinoma,3,0,0,3+,7.93,Modified(Schedule),"12 cycles of paclitaxel,trastuzumab every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
2 cycles of trastuzumab every 3 weeks",No,No,Yes,No,3029.00,3029.00,<3,0 of 17,0,T2,N1,M0,IIb
UCHI_1127,,TCH,HR+/HER2+,sim-fGRP4YnJaL,5.234,0.05242,99,Residual,Residual,27.1 x 14.3 x 9.3,35,African American,Invasive Ductal Carcinoma,2,70,60,3+,9.9,Standard,"1 cycles of carboplatin,docetaxel,docetaxel every 0 weeks
1 cycles of trastuzumab every 3 weeks
4 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycles of carboplatin,trastuzumab every 3 weeks
2 cycles of trastuzumab every 3 weeks",No,No,Yes,No,1406.00,1406.00,<1,0 of 4,0,T2,N0,M0,IIa
UCHI_1130,,ddAC-wT,TNBC,sim-frL2SNFnJd,10.4755,0.000403,100,pCR,pCR,0 x 0 x 0,59,African American,Invasive Ductal Carcinoma,2,0,0,2+,1.1,Uncertain,EMPTY,No,No,Yes,No,3277.00,3277.00,<1,0 of 19,0,T2,N1,M0,IIb
UCHI_1131,,wT-ddAC,TNBC,sim-yrrsb1A26n,6.011625,0.000156,100,pCR,pCR,0 x 0 x 0,54,African American,Invasive Ductal Carcinoma,3,0,0,1+,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3079.00,3079.00,<1,0 of 4,0,T2,N0,M0,IIa
UCHI_1133,,TCHP,HR+/HER2+,sim-56RWeMAPef,3.789375,0.009965,99.7,pCR,pCR,0 x 0 x 0,33,Caucasian,Invasive Ductal Carcinoma,2,90,90,3+,9.4,Uncertain,1 cycle of trastuzumab,Yes,Yes,Yes,No,1801.00,1801.00,0,0 of 5,0,T1c,N0,M0,Ia
UCHI_1134,,ddAC-TH,HR+/HER2+,sim-vhpp3K31mJ,5.00075,0.00935,99.8,pCR,pCR,0 x 0 x 0,60,Caucasian,Invasive Ductal Carcinoma,2,90,0,2+,3.7,Modified,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycles of trastuzumab every 0 weeks
1 cycles of paclitaxel every 2 weeks
3 cycles of paclitaxel,trastuzumab every 2 weeks
3 cycles of trastuzumab every 3 weeks",Yes,Yes,Yes,No,2812.00,2812.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1136,,wT-ddAC,HR+/HER2-,sim-mWrsm4fRDN,42.868125,21.353805,50.2,Residual,Residual,61.2 x 49.1 x 36.7,40,African American,Invasive Ductal Carcinoma,3,20,0,1+,1.8,Uncertain,EMPTY,No,No,Yes,No,2924.00,2924.00,60,0 of 2,0,T3,N1,M0,IIIa
UCHI_1137,,wT-ddAC,HR+/HER2-,sim-TnpJsxXXWP,38.8875,15.320777,60.6,Residual,Residual,117.6 x 65.3 x 33,35,African American,Invasive Ductal Carcinoma,2,90,80,2+,1.1,Modified,FAILED: goserelin,No,No,No,Yes,1021.00,2564.00,10,12 of 14,25,T2,N1,M0,IIb
UCHI_1138,,wT-ddAC,TNBC,sim-1f4yVkAX8S,7.900125,1.00046,87.3,Residual,Residual,25 x 19 x 14.1,43,Caucasian,Metaplastic Carcinoma,3,0,0,1+,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1376.00,1376.00,10,0 of 4,0,T2,N0,M0,IIa
UCHI_1139,,wT-ddAC,TNBC,sim-cMzTM33FAE,22.7765,0.020609,99.9,pCR,pCR,0 x 0 x 0,68,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
12 cycles of paclitaxel every 1 weeks",No,Yes,Yes,No,1372.00,1372.00,0,6 of 11,16,T2,N1,M0,IIb
UCHI_1142,,wTH-ddAC,HR-/HER2+,sim-nA26Z53ByF,84.922125,0.304007,99.6,Residual,Residual,112.8 x 70.5 x 42.1,45,Caucasian,Invasive Ductal Carcinoma,3,0,0,3+,0.71,Modified(Schedule),"1 cycles of trastuzumab every 1 weeks
2 cycles of paclitaxel every 1 weeks
9 cycles of paclitaxel,trastuzumab every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,3037.00,3037.00,<1,0 of 28,0,T3,N1,M0,IIIa
UCHI_1146_1,Yes,wT-ddAC,HR+/HER2-,sim-HbJTUYeJna,0.5295,0.001611,99.7,pCR,pCR,0 x 0 x 0,50,Caucasian,Invasive Ductal Carcinoma,3,90,90,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2943.00,2943.00,5,0 of 3,0,T1c,N0,M0,Ia
UCHI_1146_2,Yes,wT-ddAC,HR+/HER2-,sim-SCSt6QdhyQ,5.87775,1.324259,77.5,Residual,Residual,22.2 x 19.1 x 13.7,50,Caucasian,Invasive Ductal Carcinoma,3,7.5,40,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,2943.00,2943.00,0,0 of 5,0,T2,N0,M0,IIa
UCHI_1149,,wT-ddAC,TNBC,sim-UdHNYmvrpm,10.611375,0.00309,100,pCR,pCR,0 x 0 x 0,73,Caucasian,Invasive Ductal Carcinoma,3,0,0,1+,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,3052.00,3052.00,0,0 of 3,0,T1b,N1,M0,IIa
UCHI_1152,,wT-ddAC,TNBC,sim-S6SUwxYnSs,9.643625,3.487762,63.8,Residual,Residual,27.6 x 26.7 x 22.7,49,,Invasive Ductal Carcinoma,3,0,0,-,1.09,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1280.00,1280.00,40,2 of 31,7,T2,N1,M0,
UCHI_1153,,wT-ddAC,HR+/HER2-,sim-8YnRXhDdTb,9.660375,0.024248,99.7,Residual,Residual,20.2 x 13.8 x 10.8,44,Caucasian,Invasive Ductal Carcinoma,2,31,44,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2861.00,2861.00,60,0 of 3,0,T2,N0,M0,IIa
UCHI_1157,,TCH,HR-/HER2+,sim-RxfrUcvFpF,41.44825,1.734516,95.8,Residual,Residual,89.9 x 82.6 x 55.1,44,African American,Invasive Ductal Carcinoma,2,0,5,+,8.4,Standard,"2 cycles of trastuzumab every 3 weeks
6 cycles of carboplatin,docetaxel,trastuzumab every 3 weeks
1 cycle of trastuzumab",No,No,Yes,No,2880.00,2880.00,<1,0 of 5,0,T2,N0,M0,IIa
UCHI_1158,,wT-ddAC,HR+/HER2-,sim-nbCWwSfaFn,15.201125,0.077669,99.5,Residual,Residual,67.9 x 32.8 x 17.4,32,Caucasian,Invasive Ductal Carcinoma,3,90,80,-,1.6,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2390.00,2390.00,5,9 of 16,8,T3,N1,M0,IIIa
UCHI_1159,,wT-ddAC,TNBC,sim-TU27yBNQAD,1.21875,7.00E-06,100,pCR,pCR,0 x 0 x 0,37,African American,Invasive Ductal Carcinoma,3,0,0,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,2334.00,2334.00,0,0 of 21,0,T2,N1,M0,IIb
UCHI_1160,,wT-ddAC,HR+/HER2-,sim-aHT7kMpEcx,11.115375,0.13811,98.8,Residual,Residual,18.6 x 13.4 x 9.9,48,Caucasian,Invasive Ductal Carcinoma,3,90,0,1+,0.71,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1049.00,1049.00,5,0 of 3,0,T2,N0,M0,IIa
UCHI_1161,,wT-ddAC,TNBC,sim-A5ypSwswgF,178.683625,102.462828,42.7,Residual,Residual,105.1 x 82.6 x 74.2,70,Caucasian,Invasive Ductal Carcinoma,2,0,0,-,1.1,Modified (Dose Reduction),"6 cycles of paclitaxel every 1 weeks
5 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,164.00,197.00,30,6 of 12,41,T4b,N2a,M0,IIIb
UCHI_1163,,wT-ddAC,HR+/HER2-,sim-seegmt1VBy,3.413375,8.10E-05,100,pCR,pCR,0 x 0 x 0,34,Caucasian,Invasive Ductal Carcinoma,3,29,0,-,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,1099.00,1099.00,0,0 of 12,0,T2,N1,M0,IIb
UCHI_1165,,TCHP,HR+/HER2+,sim-vNnNCMQ5J4,4.46825,0.362574,91.9,Residual,Residual,20.1 x 13.1 x 12.1,38,Other,Invasive Ductal Carcinoma,2,90,25,2+,7.8,Modified,"3 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
2 cycles of docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks",No,No,Yes,No,2415.00,2415.00,<1,0 of 4,0,T2,N1,M0,IIb
UCHI_1167,,wT-ddAC(Gemcitibine),TNBC,sim-G9GXdd4JeX,8.1925,0.039386,99.5,Residual,Residual,19 x 13.6 x 13.2,33,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,,Uncertain,FAILED: gemcitabine,No,No,Yes,Yes,1714.00,2540.00,50,0 of 1,0,T1c,N0,M0,Ia
UCHI_1168,,wT-ddAC,TNBC,sim-DkTmsYQyAx,6.30925,0.099905,98.4,Residual,Residual,64.5 x 25.7 x 18,31,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,,Modified (Dose Reduction),"6 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2466.00,2466.00,<1,0 of 22,0,T2,N2,M0,IIIa
UCHI_1169,,wTHP-ddAC,HR-/HER2+,sim-LkDBZtDFVx,7.944125,0.000181,100,pCR,pCR,0 x 0 x 0,23,African American,Invasive Ductal Carcinoma,3,1,0,3+,10.3,Modified,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 2 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
2 cycles of trastuzumab_TP every 3 weeks",Yes,Yes,Yes,No,2535.00,2535.00,0,0 of 7,0,T2,N2a,M0,IIIa
UCHI_1170,,TCHP,HR-/HER2+,sim-KnEWSQtATc,9.738375,0.020634,99.8,Residual,Residual,61.1 x 28.1 x 18.2,53,African American,Invasive Ductal Carcinoma,3,0,0,3+,10.2,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks",No,No,No,Yes,462.00,711.00,,8 of 25,7,T3,N2,M0,IIIa
UCHI_1171,,wT-ddAC,TNBC,sim-3RdW2fErtW,5.3895,0.018945,99.6,Residual,Residual,42.3 x 16.3 x 13.5,63,Caucasian,Invasive Ductal Carcinoma,3,0,8,2+,1.3,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,2373.00,2373.00,<1,0 of 2,0,T2,N0,M0,IIa
UCHI_1172,,TCHP,HR+/HER2+,sim-3n8rFYNURF,1.696125,0.090978,94.6,Residual,Residual,9.9 x 8.3 x 6.3,38,African American,Invasive Ductal Carcinoma,3,90,20,2+,1.9,Modified,FAILED: goserelin,No,No,Yes,No,1953.00,1953.00,<5,1 of 22,4.5,T1c,N0,M0,Ia
UCHI_1173,,wTHP-ddAC,HR+/HER2+,sim-WKS3X139Hb,8.99275,0.114473,98.7,Residual,Residual,35.8 x 26.3 x 13.3,51,African American,Invasive Ductal Carcinoma,3,90,80,+,8.8,Modified,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1485.00,1485.00,5,0 of 2,0,T2,N1,M0,IIb
UCHI_1174,,wT-ddAC,TNBC,sim-FnTymnMzxT,7.21125,0.026395,99.6,Residual,Residual,37 x 36 x 25.9,73,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,0.7,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,No,Yes,1113.00,1488.00,<5,0 of 15,0,T4b,N1,M0,IIIb
UCHI_1176,,wTHP-ddAC,HR+/HER2+,sim-g16D7TtJCw,4.697125,0.031624,99.3,Residual,Residual,44.9 x 18.2 x 17.8,44,African American,Invasive Ductal Carcinoma,3,80,50,+,7.4,Modified,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,2228.00,2228.00,5,2 of 5,0.7,T2,N1,M0,IIa
UCHI_1177,,wT-ddAC,HR+/HER2-,sim-kRrSd2JJb4,23.138375,0.000266,100,pCR,pCR,0 x 0 x 0,36,Caucasian,Invasive Ductal Carcinoma,3,60,1,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",Yes,Yes,Yes,No,2022.00,2022.00,0,0 of 2,0,T2,N1,M0,IIb
UCHI_1178,,TCHP,HR+/HER2+,sim-zaw3KaSMFa,5.497875,0.304486,94.5,Residual,Residual,28.4 x 26.4 x 25.1,43,Caucasian,Invasive Ductal Carcinoma,3,90,90,2+,2.8,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks",No,No,Yes,No,1919.00,1919.00,15,5 of 12,14,T2,N1,M0,IIb
UCHI_1179,,wT-ddAC,HR+/HER2-,sim-xSgehVWFNe,6.330625,0.021611,99.7,Residual,Residual,73.9 x 19.2 x 10.6,41,Caucasian,Invasive Ductal Carcinoma,2,94,95,-,,Modified,FAILED: goserelin,No,No,Yes,No,2190.00,2190.00,10,3 of 11,3.5,T3,N0,M0,IIa
UCHI_1180,,THP,HR+/HER2+,sim-ZT6dC7DtUw,4.313875,0.024477,99.4,Residual,Residual,54.1 x 12.9 x 9.4,47,African American,Invasive Ductal Carcinoma,2,50,25,+,7.7,Modified(Schedule),"1 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
5 cycles of docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1602.00,1602.00,,0 of 9,0,T2,N0,M0,IIa
UCHI_1181,,wT-ddAC,TNBC,sim-aSTRK7TbnQ,46.2615,0.001429,100,pCR,pCR,0 x 0 x 0,48,Caucasian,Invasive Ductal Carcinoma,3,0,0,-,1.1,Modified(Only 10 T cycles),EMPTY,Yes,Yes,Yes,No,2157.00,2157.00,0,0 of 7,0,T2,N0,M0,IIa
UCHI_1182,,ddAC-wT,TNBC,sim-Cbf9BJP8X6,0.49725,0.003734,99.2,pCR,pCR,0 x 0 x 0,45,Caucasian,Invasive Ductal Carcinoma,3,5,0,-,,Standard,"4 cycles of cyclophosphamide,doxorubicin every 2 weeks
12 cycles of paclitaxel every 1 weeks",Yes,Yes,Yes,No,2097.00,2097.00,0,0 of 3,0,T1c,N0,M0,Ia
UCHI_1184,,ddAC-Tcarbo,TNBC,sim-v2n97ATKCv,2.347375,0.00016,100,pCR,pCR,0 x 0 x 0,29,Caucasian,Invasive Ductal Carcinoma,3,0,0,2+,1.4,Modified(per notes): Tcarbo x 11,EMPTY,No,No,Yes,No,2026.00,2026.00,20,3 of 20,13,T1c,N0,M0,Ia
UCHI_1186,,wTHP-ddAC,HR-/HER2+,sim-ZxSVBzEVUN,10.316625,1.60E-05,100,pCR,pCR,0 x 0 x 0,59,Caucasian,Invasive Ductal Carcinoma,3,0,0,3+,,Standard,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel,trastuzumab_TP every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of trastuzumab_TP",Yes,Yes,Yes,No,1483.00,1483.00,0,0 of 2,0,T1b,N1,M0,IIa
UCHI_1187,,wT-ddAC,HR+/HER2-,sim-dBRkDLhGHp,71.460625,13.715399,80.8,Residual,Residual,80.2 x 78.4 x 71.5,47,African American,Invasive Ductal Carcinoma,3,90,40,-,1.1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1825.00,1825.00,2,1 of 14,7,T3,N1,M0,IIIa
UCHI_1188,,wTHP-ddAC,HR+/HER2+,sim-FX9tyCHbsS,5.428875,0.010261,99.8,Residual,Residual,33.9 x 14.9 x 14.6,58,Caucasian,Invasive Ductal Carcinoma,3,50,50,2+,2,Modified,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1932.00,1932.00,5,0 of 4,0,T3,N0,M0,IIb
UCHI_1190,,TCHP,HR-/HER2+,sim-UxXfALkwfN,8.944625,0.051541,99.4,Residual,Residual,14.5 x 13.4 x 12.7,44,African American,Invasive Ductal Carcinoma,3,0,0,3+,8.6,Standard,"6 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1757.00,1757.00,30,3 of 4,2.5,T2,N1,M0,IIb
UCHI_1191,,TCHP,HR+/HER2+,sim-cYrQs1hZQB,30.860375,0.104603,99.7,Residual,Residual,78.1 x 24.9 x 17.2,69,Caucasian,Invasive Ductal Carcinoma,3,95,95,3+,,Standard,"4 cycles of carboplatin_TP,docetaxel_TP,pertuzumab_TP,trastuzumab_TP every 3 weeks
1 cycles of trastuzumab_TP every 3 weeks
1 cycles of carboplatin_TP,docetaxel_TP,trastuzumab_TP every 3 weeks
1 cycle of trastuzumab_TP",No,No,Yes,No,1772.00,1772.00,3,0 of 3,0,T3,N0,M0,IIb
UCHI_1192,,wT-ddAC,HR+/HER2-,sim-d6Y2c6SGmW,11.737,1.604193,86.3,Residual,Residual,57.4 x 50.1 x 16.8,37,Caucasian,Invasive Ductal Carcinoma,3,25,0,-,1,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1688.00,1688.00,5,1 of 6,2,T2,N1,M0,IIb
UCHI_1195,,TCHP,HR+/HER2+,sim-rXEBGx345a,19.47275,0.107905,99.4,Residual,Residual,69.6 x 39.8 x 22.1,27,Caucasian,Invasive Ductal Carcinoma,3,80,70,3+,10.5,Modified,FAILED: leuprolide,No,No,Yes,No,1304.00,1304.00,,0 of 8,0,T3,N0,M0,IIb
UCHI_1199,,wT(nab)-ddAC,HR+/HER2-,sim-SHPzwTNZEx,59.173625,0.165353,99.7,Residual,Residual,79.7 x 44.5 x 25.5,54,Other,Invasive Ductal Carcinoma,2,90,0,-,,Modified(T + Schedule),"1 cycles of paclitaxel every 15 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1343.00,1343.00,,3 of 13,11,T2,N1,M0,IIb
UCHI_1201,,wT-ddAC,TNBC,sim-T3fKN3gyts,24.761625,0.109779,99.6,Residual,Residual,52.3 x 36.3 x 30.3,48,Other,Invasive Ductal Carcinoma,3,0,0,-,,Standard,"12 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks",No,No,Yes,No,1265.00,1265.00,10,0 of 2,0,T2,N0,M0,IIa
UCHI_1202,,wTHP-ddAC,HR-/HER2+,sim-eS3XJMXMPp,9.454,4.00E-06,100,pCR,pCR,0 x 0 x 0,47,Caucasian,Invasive Ductal Carcinoma,3,0,0,3+,8.1,Standard,"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
1 cycle of pertuzumab_TP,trastuzumab_TP",Yes,Yes,Yes,No,1322.00,1322.00,0,0 of 3,0,T2,N0,M0,IIa
UCHI_1203,,wTHP-ddAC,HR-/HER2+,sim-W5m4YE8rcH,66.475625,5.00E-05,100,pCR,pCR,0 x 0 x 0,34,Other,Invasive Ductal Carcinoma,3,0,0,+,2.5,Modified (Dose reduced T),"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
4 cycles of cyclophosphamide,doxorubicin every 2 weeks
3 cycles of trastuzumab_TP every 3 weeks
1 cycle of pertuzumab_TP,trastuzumab_TP",Yes,Yes,Yes,No,581.00,581.00,0,0 of 4,0,T3,N1,M0,IIIa
UCHI_1209,,ddAC-wT,HR+/HER2-,sim-GFGtvNP6tR,25.268375,0.235168,99.1,Residual,Residual,67.2 x 56.5 x 34.4,42,Asian,Invasive Ductal Carcinoma,3,90,10,-,1.5,Uncertain,"4 cycles of cyclophosphamide,doxorubicin every 3 weeks
9 cycles of paclitaxel every 1 weeks",No,No,Yes,No,933.00,933.00,70,3 of 18,20,T2,N1,M0,IIb
UCHI_1222,,THP-ddAC,HR-/HER2+,sim-L5h9PUNbT8,41.985375,7.80E-05,100,pCR,pCR,0 x 0 x 0,56,,Invasive Ductal Carcinoma,3,0,0,3+,5.1,Modified (Dose reduced T),"1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
2 cycles of paclitaxel every 1 weeks
1 cycles of paclitaxel,pertuzumab_TP,trastuzumab_TP every 1 weeks
1 cycles of paclitaxel every 2 weeks
4 cycles of cyclophosphamide,doxorubicin every 4 weeks
5 cycles of pertuzumab_TP,trastuzumab_TP every 3 weeks
2 cycles of trastuzumab_TP every 3 weeks
1 cycles of pertuzumab_TP,trastuzumab_TP every 3 weeks
5 cycles of trastuzumab_TP every 3 weeks",No,Yes,Yes,No,695.00,695.00,0,2 of 24,0.5,T3,N1,M0,